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ABSTRACT
Introduction: Drug-resistance is a major hindrance to successful treatment of AML.  Current predictive biomarkers 
are mainly genetic aberrations and insufficient in foretelling treatment outcome in all acute myeloid leukaemia (AML) 
due to its heterogeneous and aggressive nature.  Proteins are stable and reliable. Secreted proteins in AML may have 
predictive or prognostic values for early intervention.  Proteomic studies on AML are few and further investigations 
will benefit in selection of best markers.   The aim of the study was to identify differentially expressed plasma proteins 
in AML with different treatment outcome.  Methods: Two-dimensional electrophoresis (2-DE) technique was utilised 
to identify proteins differentially expressed in chemo-sensitive/chemo-resistant AML.  Plasma and peripheral blood 
mononuclear cell (PBMC) lysate proteome analysis were performed on six chemo-resistant, four chemo-sensitive and 
six healthy controls and seven chemo-resistant, three chemo-sensitive and six healthy controls, respectively.  Each 
experiment was conducted in duplicate or triplicate.  Images were captured and protein spots detected by software. 
Differentially expressed protein spots were excised from gel and proteins were identified using LC/MS/MS.  Proteins 
spots that were also detected in healthy controls were excluded.  Results: Comparing mean % volume of each spot 
demonstrated significantly enhanced expression of apoliprotein-E (APO-E) and haptoglobin (HP) (p<0.05) in plasma 
and HNRNP H1 (p=0.049) in cell lysate of chemo-sensitive group. Serotransferrin (STF) from plasma and DNA-PK 
from cell lysate (p=0.01) were associated with chemo-resistance. Conclusion: This preliminary study identified sever-
al potential predictive biomarkers associated with chemo-resistance/chemo-sensitivity to treatment in AML.  Further 
studies with a larger number of samples are required to validate the results. 
  
Keywords:  Proteomics, Acute myeloid leukaemia, Two-dimensional electrophoresis; Mass spectrometry; Chemo-re-
sistance.





Acute myeloid leukaemia (AML) arises from the aberrant 
proliferation of hematopoietic myeloid progenitors 
which also demonstrates a partial block in cell maturation 
(1). Immature leukaemic blasts originate from the bone 
marrow and accumulate in the peripheral blood. 
Intensive chemotherapy is a standard treatment and 
the aim of induction chemotherapy is to achieve 
complete remission (CR) (2).  Stem cell transplantation 
has further improved cure rates, however, this has 
limited application. Initial respond to treatment is more 
favourable in younger AML patients as the majority 
achieve CR (65-75%) but is less so among the elderly 
patients (40-50%) (1). The rest are drug resistant.  Most 
patients relapse within three years after initial CR and 
many become resistant to further chemotherapy (3, 4).  
Several chromosomal translocations and gene mutations 
are recommended by the World Health Organisation 
(WHO) as prognostic markers in classification of AML (5), 
however, these are unavailable to a substantial number, 
for example, those who are normal for cytogenetics or 
gene mutations.
Screening for potential biomarkers in diagnosis, 
prognosis, monitoring and therapy of cancers including 
AML has been actively investigated and with the use 
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of high throughput technologies has generated vast 
amount of data. However, due to the heterogeneous as 
well as the aggressive nature of AMLs which requires 
close monitoring, pathophysiology of the complete 
disease is only beginning to be clear.  Development of 
personalized medicine is expected to greatly improve 
long-term survival of chemo-resistant patients but is not 
expected to be without challenges [reviewed in (6)]. 
Genetic aberrations such as translocations involving 
MLL-AML, CBF, point mutations affecting FLT-3 and 
NPM1 are routinely tested.  Nevertheless, random 
translocations/mutations involving other genes are 
frequently observed in AML.  Abnormally up-regulated 
mediators of signalling pathways in JAK/STAT, Raf/MEK/
ERK and PI3K/AKT (7,8)  as well as leukaemia stem cells 
have been implicated in promoting survival and resisting 
chemotherapy in AML (9,10).  Epigenetic changes due 
to hyper/hypo methylation, associated non-coding 
RNAs and proteomics contributions to AML prognosis 
are still under study [reviewed in (11)].  Bai et al. (12) 
profiled AML peptidomes to identify serum candidates in 
minimal residual disease samples to predict impending 
relapse and identified 47 potential biomarkers including 
increased UBA1, and decreased isoform 1 of fibrinogen 
alpha chain precursor and platelet factor 4(PF4) in newly 
diagnosed and relapsed+refractory AML.   Nevertheless, 
biomarkers of refractory/chemo-resistance in newly 
diagnosed cases may differ.
Proteins are the functional components of a cell. Its 
stability permitted many of the long established, reliable 
protein-based diagnostic markers critical in clinical 
settings.  Test methods range from easy to use, rapid 
results to full automation.  Due to gene regulation at 
the transcriptional and post-transcriptional level, protein 
abundance and RNA expression levels rarely exhibit a 
linear correlation (13).
Powerful technologies in microarrays and proteomic 
approaches including mass spectrometry have made it 
possible to discover and identify new markers.  Novel 
tools in protein detection with aptamers, peptoids and 
small molecules will super advance diagnostics, as it did 
before with antibodies (14).  
Investigation on protein biomarkers in AML is still 
inconclusive. The aim of this study was to identify 
proteins associated with outcome from chemotherapy 
in AML at initial diagnosis from plasma and peripheral 




Peripheral blood samples were collected from newly 
diagnosed AML patients admitted to Hospital Ampang 
between July 2009 and July 2011. Included were patients 
of all ages, both sexes and Malaysians.  Excluded were 
samples from chemotherapy treated patients, patients 
without complete induction therapy, and insufficient 
samples. Samples were collected after informed consent 
from patients. This study was approved by the Medical 
Research Ethics Committees at Institutional and Ministry 
of Health, Malaysia.  All procedures were in accordance 
with The Code of Ethics of the World Medical Association 
(Declaration of Helsinki). AML treatment was according 
to the Berlin-Frankfurt-Munich (BFM)-83 protocol with 
modifications.  All clinical and pathological data were 
obtained from hospital records.  Diagnosis of AML 
patients was based on presence of more than 20% of 
myeloblast defined by morphology, cytochemistry and 
immunophenotyping according to guidelines from the 
2016 revision of World Health Organisation classification 
of myeloid neoplasms and acute leukaemia (5). Criteria 
for chemotherapy resistance status were based on bone 
marrow examination, showing > 5 % blast cells after 
recovery from induction chemotherapy. The patients 
were categorized as chemotherapy resistant or sensitive/
responder, where chemotherapy sensitive/responder 
patients achieved complete remission (i.e. <5% blasts 
in bone marrow) as diagnosed in bone marrow report, 
one month after induction therapy. For proteomic study 
of PBMC, 10 AML patients (chemo-resistant = 7, chemo-
sensitive = 3) and 6 normal controls (3 males, 3 females) 
were included while for plasma analysis, 10 AML 
patients (chemo-resistant = 6, chemo-sensitive = 4) and 
6 normal controls (3 males, 3 females) were included in 
this study. 
PBMC and plasma samples preparation
Peripheral blood was separated by gradient density 
centrifugation on Ficoll-Hypaque Plus (GE Healthcare, 
Sweden) to isolate peripheral blood mononuclear 
cells (PBMC).  Washed pellet was resuspended in 
cryopreservation medium consisting of 10% DMSO 
(Ameresco, USA) and 40% FBS (Gibco®, Invitrogen, 
South America) in RPMI 1640 (Gibco®, Invitrogen, 
South America) and stored over liquid nitrogen. Plasma 
layer was transferred into tubes and stored at -80oC until 
further analysis. 
To perform 2-DE, frozen tubes were quick thawed and 
PBMC was washed.  Pellets containing 107 cells were 
solubilised in 200 µl lysis buffer.   For plasma samples, 20 
µl was added to 100 µl lysis buffer.  Lysis buffer consisted 
of 7M urea (Bio-Rad, USA), 2M thiourea (Sigma, USA), 
4% (w/v) CHAPS (Amresco, USA), 2% IPG (Immobilized 
pH Gradient) buffer pH 3-10 nonlinear (GE Healthcare- 
Sweden), 0.5 % Triton X-100 (Amresco, USA), 1% (w/v) 
DTT (Amresco, USA), 1% nuclease mix (GE Healthcare, 
Sweden) and 1% protease inhibitor mix (GE Healthcare, 
Sweden).  
Following lysis, PBMC samples were centrifuged at 
16,000 xg at 4oC for 45 minutes.  The supernatant was 
cleaned with 2D-CleanUp Kit (GE Healthcare, Sweden) 
to reduce salt and other contamination. For plasma 
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samples, proteins were subjected to immunodepletion of 
albumin and IgG with the albumin IgG removal kit (GE, 
Healthcare, Sweden) and acetone precipitated to enrich 
for low abundant proteins and increase resolution. 
For acetone precipitation, 10 µl was mixed with four 
volumes of ice-cold acetone and left at -20oC overnight. 
Protein pellet was then obtained by centrifugation at 
16,000 xg for 10 min at 4oC. Acetone was decanted and 
pellet air dried for 5 minutes at room temperature. 
Precipitated proteins were resuspended in the same 
lysis buffer and protein concentration was determined 
with a Bio-Rad Protein Assay kit (Bio-Rad, USA) based 
on Bradford protein test. Lysate samples were aliquoted 
and stored at -80oC.
Two dimensional electrophoresis (2-DE)
For isoelectric focusing of PBMC samples, 7 cm IPG 
strips, pH 3-10 nonlinear (GE Healthcare, Sweden) were 
used while for plasma samples, isoelectric focusing 
was conducted on 17 cm IPG strips, pH3-10, nonlinear 
(GE Healthcare, Sweden) to increase protein loading. 
Passive rehydration with 30 µg of protein lysate took 
place in rehydration buffer containing 7 M urea, 2 M 
thiourea, 4% (w/v) CHAPS, 0.2% IPG buffer (pH 3-10 
NL, GE Healthcare) and 0.002% bromophenol blue for 
18 hrs. Isoelectric focusing was performed at 20oC using 
PROTEAN IEF cell (Bio-Rad, USA). Standard focusing 
program, recommended by manufacturer was applied 
with some modifications as follows: 250 V in a linear 
gradient over 40 minutes, a linear gradient to 4000V 
over 2 hours, 4000 V until 10000 V/h in a ramping 
mode. 
For equilibration of focused proteins, strips were 
incubated in equilibration buffer (0.05 M Tris-HCl, pH 
8.8, 6 M urea, 30% glycerol, 2% SDS, and 0.001% 
bromophenol blue) containing 2% DTT for 15 min 
followed by further incubation in the same equilibration 
buffer  but with 2.5% iodoacetamide instead of DTT for 
an additional period of 15 min. 
For second dimension electrophoresis, proteins were 
separated on 12.5% SDS-polyacrylamide gel (Mini-
PROTEAN Tetra Cell electrophoresis system, Bio-Rad).
The voltage was set initially at 50 V for 30 minute 
followed by 100 V until the tracking bromophenol 
blue dye reached the end of the gel. Gels were stained 
with silver stain plus kit (Bio-Rad, USA) according to 
manufacturer’s instruction. Each sample was run in 
triplicate to reduce technical variation.
Scanning and image analysis
Images of two dimensional electrophoresis gels were 
captured using Image Scanner (GE Healthcare, Sweden) 
with 300 dots per square inch (dpi). Protein spots were 
detected automatically using the ImageMaster 2D 
Platinum software, version 7.0 (GE Healthcare, Sweden). 
To analyse protein expression levels, percentage of 
volume contribution (% vol) was used. All values are 
presented as mean ± S.E.M (standard error of the mean).
Protein identification by liquid chromatography/mass 
spectrometry/mass spectrometry (LS/MS/MS)
Selected protein spots were manually excised and 
outsourced for LC/MS/MS analysis at Proteomics 
International Pty Ltd (Australia). Mascot sequence 
matching software (Matrix Science) with Ludwig NR 
database was used.  Proteins were identified based 
on statistically significant molecular weight search 
(MOWSE) score (p < 0.05).
Statistical analysis
All values were expressed in mean ± SEM. Non-
parametric Mann-Whitney U test was performed to 
compare median percentage of spots volume between 
two groups. A p value < 0.05 was considered significant.
 
RESULTS  
Clinical data and diagnosis
Clinical details of AML patients included in this study 
are listed in Table I.  Mean age of patients was 38 years 
(range19-66 years).  There were more female (58.3%) 
than male patients.  Majority of the samples were used 
for both peripheral blood mononuclear cell (PBMC) and 
















1 51H M1 F D+A 33
2 54H M1/M2 F D+A 34
3 56H M4 M M+A 64
4 32H M4 M M+A 66
5 52H M1 F D+A 51














9 33H M5b M D+A 36
10 43H M2 F D+A 47
11 53H ND M I+A 19
12 49H* ND F D+A 57
aFAB : French-American-British classification system. ND= Not determined
bTreatment: A= Ara-C, D= Daunorubicine, I= Idarubicin, M=Mitoxantrone
*Only plasma sample  #Only PBMC sample
plasma analysis.
2-DE gel analysis 
Three separate experiments were performed for all 
samples except two where the amount of protein was 
insufficient. Similar protein spot patterns were obtained 
for all groups. Representative 2-DE gel images for each 
group are shown in Fig. 1 and Fig. 2. Approximately 
1070 protein spots were detected in PBMC samples in 
silver stained gels. Scanned images were firstly analysed 
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using the ImageMaster software then checked manually. 
Spots >4 fold changes were chosen as differential spots 
between resistant and sensitive groups. Two spots 
expressed significantly different in the two patient groups 
were selected, excised and sent for mass spectrometry 
(MS) analysis. Spot No. 169 (p=0.01) was overexpressed 
in resistant group (Fig. 1) while Spot No. 503 (p=0.049) 
was up-regulated in the chemo-sensitive group.
In plasma samples approximately 560 spots were 
detected. Among them, a total of eight proteins were 
significantly different in plasma of resistant and sensitive 
patients. Five high molecular weight (HMW, MW~70 
kDa) spots were expressed in 3/6 chemo-resistant 
samples and absent from the other groups.  Of these 3 
were selected for mass spectrometry analysis. Spots No. 
177 (<20 kDa) and 178 (~36 kDa) were significantly 
overexpressed in chemo-sensitive group (P<0.05).
Protein identification by LC/MS/MS 
Representatives of full 2-DE gel images of PBMC 
and plasma samples are shown in Fig. 1 and Fig. 2, 
respectively.  Proteins spots differentially expressed in 
chemo-resistant and chemo-sensitive AML PBMC and 
plasma are shown in Fig. 1B and Fig. 2B, respectively. 
Characteristics of the individual protein spots identified 
by LC/MS/MS analysis in PBMC and plasma samples are 
shown in Table II and Table III, respectively.
Figure 1: A) Representative full 2-DE gel images of PBMC 
samples. B) Close-up 2-DE gel images of differentially ex-
pressed protein spots in chemo-resistant, chemo-sensitive 
and healthy controls from PBMC samples.
Figure 2: A) Representative full 2-DE gel images of plasma 
samples. B) Close-up 2-DE gel images of differentially ex-
pressed protein spots in chemo-resistant, chemo-sensitive 
and healthy controls from plasma samples.
Table II: Characteristics proteins from PBMC lysate identified by LC/MS/MS differentially expressed in chemo-resistant and chemo-sensitive 
AML 
Spot No. NCBI Accession No. Sequence 
coverage
Protein name MW (Da) PI Score Peptides 
(Unique)
169 NP_005511.1 4%
Heterogeneous nuclear  ribonucleoprotein 








45221 8.28 52 1
For PBMC proteins, Spot No.169 was successfully 
identified as heterogeneous nuclear ribonucleoprotein 
H1 (HNRNP H1). Identification of Spot No. 503 was not 
successful and reported as a putative uncharacterized 
protein of Streptococcus downei.  However, by blasting 
the peptide sequence with NCBI database against Homo 
sapiens, protein DNA-PK (DNA-dependent protein 
kinase) was found as a hit (Table II).  
For plasma proteins, two spots (Spot No. 177 and 178) 
and a set of high molecular weight (HMW) proteins of 
similar molecular weight were differentially expressed in 
the AML groups and absent in normal controls (Fig. 2). 
LC/MS/MS identified Spot. No. 177 as haptoglobin (HP). 
Spot. No. 178 was identified as apoliprotein-E (APO-E). 
All three HMW spots selected (HMW 1, 2 and 3) aligned 
to basically two proteins, serotransferrin (STF) or in short 
for transferrin (TF) and Ig mu chain C region (IGHM) (Fig. 
2, Table III).  TF and IGHM have high molecular weights 
at 80 kDa and 65 kDa, respectively.  However, TF is 
closer to the observed molecular weight for these spots 
and thus, is likely the differentially expressed protein.
Annotation and function of proteins were retrieved from 
protein databases such as UniProt and NCBI websites.
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normal functional abilities (21).  Spot 178 was identified 
as apoliprotein E isoform b precursor (NP_000032.1). 
ApoE3 is identified as an Identical Protein Group 
(https://www.ncbi.nlm.nih.gov/ipg/NP_000032.1). 
These proteins are apparently not differentiated at the 
protein level.   Braoudaki et al. (22) analysed serum 
samples from acute lymphoblastic leukaemia (ALL) and 
identified APO-E at similar position in 2-DE proteome 
as this study but found it to be associated with high 
risk ALL. This is in contrast to increased expression in 
chemo-sensitive cases here.  However, it is increased in 
ovarian cancers and expression in nuclei was associated 
with better survival (23). Women with APOE4 genotype 
survived significantly longer than non-APOE4 chronic 
lymphocytic leukaemia (CLL) patients (24).  A study 
on serum from AML patients found it to be absent in 
contrast to normal controls (25).  Thus, importance of 
APO-E in cancer and leukaemia may be subjected to its 
various isoforms.  
Haptoglobin (HP) is a serum protein essential in acute-
phase response during inflammation with an important 
inhibitory function (26).  It combines with plasma 
haemoglobin for recycling of heme iron.  This complex 
is picked up by macrophage CD163 scavenger receptor 
and degraded through the endocytic lysosomal pathway 
in liver Kupffer cells.  Haptoglobin was identified 
on three regions on 2-DE with nonlinear IPG strip on 
the pH range 3-10 (27) where the smallest molecular 
weight corresponded to truncated alpha-chain proteins 
of haptoglobin as identified here.  Increased HP1 in 
leukaemias has been reported since the 1960s (28).  In 
AML, HP was significantly elevated compared to controls 
(29).  Mitchell et al. (28) examined HP phenotypes in 
AML and showed frequency of HP1 was increased while 
HP2 was decreased compared to controls.  HP2-1 and 
HP0 phenotypes were also identified.  A more recent 
study showed HP2 was elevated in AML in contrast 
to normal control (25).   Haptoglobin-1 precursor was 
significantly increased in all grades of ovarian cancer 
Table III: Characteristics of plasma proteins identified by LC/MS/MS differentially expressed in chemo-resistant and chemo-sensitive AML






178 NP_000032.1 31% Apolipoprotein E precursor 36123 5.65 557 11
HMW 1 B4E1B2 19% cDNA FLJ53691, highly similar to Serotrans-
ferrin 
74783 6.81 689 25
P01871 26% IGHM Ig mu chain C region 49276 6.35 616 21
B2R8I2 17% cDNA, FLJ93914, highly similar to Homo 
sapiens histidine-rich glycoprotein (HRG), 
mRNA
59475 7.01 362 11
HMW 2 B4E1B2 24% cDNA FLJ53691, highly similar to Serotrans-
ferrin
74783 6.81 651 24
P01871 27% IGHM Ig mu chain C region 49276 6.35 632 23
HMW 3  B4E1B2 8% cDNA FLJ53691, highly similar to Serotrans-
ferrin
74783 6.81 170 7
 P01871 13% IGHM Ig mu chain C region 49276 6.35 268 7
177 H3BMJ7 16% Haptoglobin 10147 4.88 379 13
DISCUSSION
In the present study 2-DE identified HNRNP H1 from 
PBMC lysate, APO-E and haptoglobin from plasma were 
significantly up-regulated in chemo-sensitive patients. 
On the other hand, DNA-PK from PBMC lysate and 
serotransferrin from plasma were significantly increased 
in chemo-resistant patients.  
HNRNP H1 belongs to a subfamily of RNA-binding 
proteins that possess three repeats of quasi-RRM domains 
and has a key role in RNA processing and metabolism. 
HNRNP H1/H2 is involved in splicing of pre-thymidine 
phosphorylase (TP) mRNA. It was demonstrated that 
abnormal splicing of TP pre-mRNA caused loss of 
expression and function of TP gene in a tumour cell line, 
therefore, resulting in resistance to fluoropyrimidine-
based anti-cancer drugs (15).  A unique glycosylated 
HNRNP H1 was found to be associated with 11q23 
translocation (16) but not other AML cytogenetic 
risk groups. An analysis of 148 AML patients showed 
presence of 11q23 did not alter overall survival (OS) 
but improved OS and relapse-free survival in allogeneic 
stem cell transplantation patients (17). HNRNP H1 is 
a putative ZEB2 interaction partner in fusion proteins 
in T-cell acute lymphoblastic leukaemia, T-ALL (18) 
and recognised as a main novel splicing regulator in 
murine AML model among novel tumour suppressors 
and oncogenes (19).   Strong HNRNP H expression was 
associated with better survival in colorectal cancer (20). 
The identification of HNRNP H1 protein here supports 
its importance as a potential predictive biomarker in 
leukaemia.
ApoE is a 299 residue protein and key regulator of 
plasma lipid levels which binds to lipid and low density 
lipoprotein receptor inducing lipolytic processing and 
endocytosis of triglyceride-rich lipoprotein. It is secreted 
by cells in the liver as well as the brain.  Three ApoE 
isoforms are recognised, E2, E3 and E4 with different 
clinical significance.  E3 is the dominant form with 
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suggesting suitability as an early diagnosis biomarker 
(30).  Our results support increased haptoglobin protein 
in AML particularly among chemo-sensitive cases.
DNA-dependent protein kinase (DNA-PK) catalyses the 
repair of DNA double-strand breaks via involvement 
of the non-homologous end-joining pathway. Cancer 
cells that are able to repair DNA damage controls their 
sensitivity to radio- or chemo-therapy.  It is widely 
accepted that increase in DNA-PK activity enhances 
resistance of cancer cells to chemotherapies since their 
DNA repair function unavoidably lead to protection 
of the cancer genome and survival of tumour cells 
(31).  DNA-PK stimulates angiogenesis, migration and 
invasion in the development of metastasis (32).  In AML, 
increased DNA-PK activity correlated with chemo-
resistance against various anti-tumour agents (33).  Our 
result on DNA-PK supports these earlier studies.
Transferrin (TF) is a serum glycoprotein for the delivery 
of iron and is a test routinely used in diagnosis of 
diseases.  Higher transferrin saturation was associated 
with increased risk of non-skin cancer and cancer death 
(34).  CD71 (transferrin receptor, TFR) is a preferred 
marker for study and was not found to be expressed 
on leukaemia cells in AML cases (35).  A proportion of 
AML blasts expressing TFR was related to proliferative 
potential and could be stimulated to proliferate (36). 
AML expressing high levels of TFR (>60%) was 30.8%, 
however, did not appear to impact survival time (37). 
The availability of this biomarker in routine test makes it 
all the more suitable as it can be easily incorporated into 
current practise in management of AML.
CONCLUSION
In conclusion, proteins selected from this study support 
findings of earlier studies in having identified the same 
proteins with potential as biomarkers in AML.  However, 
its precise role to predict treatment outcome varied 
possibly due to the heterogeneity in cancers as well 
as complexity of proteins. Future work should include 
a larger number of samples to validate the predictive 
potential of these markers.
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